Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Combination nanotherapy drastically reduces the amount of HIV produced by cells in mice

A combination of fine-particle formulations of the drugs atazanavir and ritonavir, plus an immune-dampener drug designed to induce cells to keep hold of the drugs for longer,

Published
22 hours ago
By
Gus Cairns
Adenosine deaminase may help the immune system fight HIV on its own

New research published in the Journal of Leukocyte Biology suggests that adenosine deaminase enhances anti-HIV-1 specific immune responses by reducing the action of cells that impede HIV-specific defenses

Published
03 February 2016
From
Eurekalert Medicine & Health
CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy

CytoDyn Inc. today announced that its study of a passive-antibody monotherapy, PRO 140, which is given as a weekly injection, has shown complete viral-load suppression for well over a year with some patients approaching 17 months. The Company believes that complete virologic suppression through treatment with a single agent rather than through the widely used HAART combination therapy could present a significant opportunity to treat HIV patients. CytoDyn is currently conducting a pivotal Phase 3 trial for PRO 140 with expected commercialization in 2017.

Published
27 January 2016
From
Cytodyn Inc.
Experimental Combination Surprises with Anti-HIV Effectiveness

A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected. The potency of the combination treatment, tested so far in mice, suggests that it would be possible to rid the body of HIV for months, reducing the frequency with which patients must take these medications from daily to several times a year.

Published
27 January 2016
From
National Institute of Mental Health
IV and Injectable HIV Treatments Are Much Discussed -- But Won't Be Here Anytime Soon

Given the success of currently available oral therapies -- in which essentially 100% of people who take it are virologically suppressed -- why do so many people say they want injectable shots instead?

Published
21 January 2016
From
TheBody Pro
ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

ABX464 is a first-in-class orally available antiviral drug candidate for the treatment of patients with HIV infection. It blocks HIV replication through a unique mechanism of action that leads to the destruction of viral RNA. A dose-dependent increase in the response rate to ABX464 monotherapy was observed in the study. The majority of patients who received the highest dose (150 mg) showed a viral load reduction of at least 0.5 log (greater than 68% reduction) during the treatment period.

Published
13 January 2016
From
Medical News Today
Janssen, ViiV Healthcare Formalize Injectable Rilpivirine + Cabotegravir Phase 3 as HIV Treatment

Janssen Sciences Ireland UC (Janssen), formalized its collaboration with ViiV Healthcare on phase III development and commercialization of a two drug regimen of two long acting, all-injectable formulations of rilpivirine (a non-nucleoside reverse transcriptase inhibitor by Janssen) and cabotegravir (ViiV Healthcare).

Published
08 January 2016
From
Street Insider
HIV Antibody Infusion Safely Suppresses Virus in Infected People

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today.

Published
24 December 2015
From
National Institute of Allergy and Infectious Diseases (NIAID)
Scientists reveal new phase of HIV infection

A new life cycle stage in HIV infection has been identified thanks to a novel technique they developed to take images of intact infected cells. Researchers have shown that this phase of infection, dubbed intra-nuclear migration, relies on the human protein CPSF6 to guide the virus through the host cell's nucleus and position it at active genes where it prefers to make its home.

Published
19 December 2015
From
Science Daily
Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare

Bristol-Myers Squibb Company today announced that it has entered into two individual agreements with ViiV Healthcare, a global HIV company, to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development. The agreements with ViiV Healthcare do not impact Bristol-Myers Squibb’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla. Bristol-Myers Squibb remains committed to the commercialization of these products and to those patients who rely on these medicines.

Published
18 December 2015
From
Bristol-Myers Squibb press release
← First12345...88Next →

Filter by country